Myeloproliferative Neoplasms News & Features
Recommended Therapies for Polycythemia Vera Underused
Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients.
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
Results of an open-label phase 2 study demonstrated that a dose-escalation approach can prevent worsening anemia in patients with myelofibrosis undergoing treatment with ruxolitinib.
Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
In a review of data from DANHES study, researchers determined the hazard ratio for developing myeloproliferative neoplasm — any or by subtype — among smokers, occasional smokers, and ex-smokers, compared with never smokers.
Case Study: Myelofibrosis Diagnosis and Early Intervention
In this Case Study, Ms Lyle discusses diagnosis and early management of myelofibrosis in a 72-year-old male patient.
Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.
Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.
Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.
Effect of Myeloproliferative Neoplasm Diagnosis on Work, Employment Status
Using a cross-sectional online survey, researchers sought to determine how a MPN diagnosis affects work productivity and employment for patients with polycythemia vera, essential thrombocytopenia, or myelofibrosis.
Sign Up for Free e-newsletters
ONA Articles
- Proscription on Antiperspirant Use During Radiotherapy: Does the Advice Still Apply?
- Recommended Therapies for Polycythemia Vera Underused
- FDA Grants Approval to New Treatment for Acute Myeloid Leukemia
- Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma
- Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value
- Smartphone App Improves Management of Cancer-Related Pain, Anxiety
- Counseling Patients on Oral Chemotherapy
- Lung Cancer-Specific Distress Screening Tool Not Needed But Has Potential Benefit
- Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Expression of Chemerin Correlates With a Poor Prognosis in Female Breast Cancer Patients
- Proscription on Antiperspirant Use During Radiotherapy: Does the Advice Still Apply?
- Recommended Therapies for Polycythemia Vera Underused
- Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value
- Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |